Oruka Therapeutics

Yahoo Finance • yesterday

Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibo... Full story

Yahoo Finance • 2 days ago

Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

Oruka Therapeutics (ORKA [https://seekingalpha.com/symbol/ORKA]) has announced an upsized public offering [https://seekingalpha.com/pr/20491699-oruka-therapeutics-announces-pricing-of-upsized-700-million-underwritten-public-offering] of 9.... Full story

Yahoo Finance • 3 days ago

Oruka Therapeutics Prices Upsized $700 Mln Offering To Advance Psoriasis Pipeline

(RTTNews) - Oruka Therapeutics, Inc. (ORKA), has priced an upsized $700.4 million underwritten public offering, strengthening its balance sheet as the company advances two late-stage dermatology programs designed for ultra-infrequent dosin... Full story

Yahoo Finance • 3 days ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory... Full story

Yahoo Finance • 4 days ago

Tech Earnings Optimism Powers Stocks Higher

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.01%.  June E-mini S&P futures (ESM26) rose +0.14%, and June E... Full story

Yahoo Finance • 4 days ago

Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.30%.  June E-mini S&P futures (ESM26) are down -0.14%, and June E-mini Na... Full story

Yahoo Finance • 4 days ago

Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX) (SPY) today is unchanged, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.10%.  June E-mini S&P futures (ESM26) are down -0.02%, and June E-mini Nasdaq... Full story

Yahoo Finance • 4 days ago

How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise

Nearly two-thirds of patients who received Oruka Therapeutics' experimental psoriasis treatment had completely clear skin after 16 weeks. Continue Reading... Full story

Yahoo Finance • 5 days ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin... Full story

Yahoo Finance • 11 days ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • 15 days ago

Oruka Therapeutics price target raised to $85 from $45 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $85 from $45 and keeps an Outperform rating on the shares. The firm reviewed anticipated benchmarks and stock setup for upcoming induction data from the Phase 2a EVERLA... Full story

Yahoo Finance • last month

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • last month

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 2 months ago

VR Adviser Adds Over 1 Million Savara Shares

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued... Full story

Yahoo Finance • 4 months ago

Wednesday's ETF Movers: XBI, SLVR

In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oruka Therapeutics, up about 5.5% and shares of Arcutis Biothera... Full story

Yahoo Finance • 6 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2... Full story

Yahoo Finance • 6 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin... Full story

Yahoo Finance • 7 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 7 months ago

Oruka Therapeutics files to sell 39.43M shares of common stock for holders

* Oruka Therapeutics (NASDAQ:ORKA [https://seekingalpha.com/symbol/ORKA]) has filed to sell 39,425,806 shares of common stock for holders. * This prospectus is not an offer to sell these securities. * Filing [https://seekingalpha.com... Full story

Yahoo Finance • 7 months ago

MoonLake rebounds despite downgrades prompted by trial setback

[Sign for Wall Street in New York City] Pharrel Wiliams MoonLake Immunotherapeutics (NASDAQ:MLTX [https://seekingalpha.com/symbol/MLTX]) traded higher on Tuesday even as Wall Street opted to downgrade the Swiss biotech following a late-st... Full story